Partnership hopes to improve large-scale exosome production


Bio-chromatography company Sartorius BIA Separations (BIA) and exosomes medicines company Exopharm have signed a Material Transfer Agreement and associated collaborative programme. 

The partnership aims to combine Exopharm’s LEAP technology together with BIA’s CIM (Convective Interaction Media) monolith chromatography for improved large-scale therapeutic exosome production and commercialisation. 

The companies hope to meet the demand for a large-scale, high-efficiency purification technology that overcomes critical issues associated with the production of clinical-quality exosomes as delivery vehicles for gene-based therapeutics. 

Exosomes are emerging as an effective, non-viral chassis for genetic medicines, as they are non-toxic, efficient at delivering RNA cargoes into cells and able to do so without eliciting an immune response.  

Initial research efforts between BIA and Exopharm will focus on the assessment and validation of the addition of LEAP ligand chemistry to CIM monolithic columns. BIA also aims to determine the optimal immobilisation density of LEAP ligands for high-throughput, large scale production of purified exosomes. 


Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free